SR/Hsd |
plasma sodium level |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
139.6 |
mmol/l |
2.1 |
5.14 |
flame atomic emission spectrometry |
0.0 |
0 |
102233 |
2682 |
SS/Hsd |
plasma sodium level |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) then sham surgical control condition (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
140.3 |
mmol/l |
1.3 |
3.18 |
flame atomic emission spectrometry |
0.0 |
0 |
102253 |
2682 |
SR/Hsd |
plasma sodium level |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
140.4 |
mmol/l |
1.4 |
3.43 |
flame atomic emission spectrometry |
0.0 |
0 |
102236 |
2682 |
SS/Hsd |
plasma sodium level |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
140.7 |
mmol/l |
2.2 |
5.39 |
flame atomic emission spectrometry |
0.0 |
0 |
102244 |
2682 |
SS/Hsd |
plasma sodium level |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
140.6 |
mmol/l |
2.4 |
5.88 |
flame atomic emission spectrometry |
0.0 |
0 |
102241 |
2682 |
SS/Hsd |
plasma sodium level |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) then surgical denervation (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
141.1 |
mmol/l |
1.8 |
4.41 |
flame atomic emission spectrometry |
0.0 |
0 |
102254 |
2682 |
SR/Hsd |
plasma sodium level |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
140.3 |
mmol/l |
1.8 |
4.41 |
flame atomic emission spectrometry |
0.0 |
0 |
102234 |
2682 |
SS/Hsd |
plasma sodium level |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
140.2 |
mmol/l |
2.1 |
5.14 |
flame atomic emission spectrometry |
0.0 |
0 |
102242 |
2682 |
SR/Hsd |
plasma sodium level |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) then surgical denervation (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
139.6 |
mmol/l |
1.4 |
3.43 |
flame atomic emission spectrometry |
0.0 |
0 |
102250 |
2682 |
SR/Hsd |
plasma sodium level |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) then sham surgical control condition (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
139.8 |
mmol/l |
0.7 |
1.71 |
flame atomic emission spectrometry |
0.0 |
0 |
102251 |
2682 |
SR/Hsd |
plasma sodium level |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
139.3 |
mmol/l |
1.6 |
3.92 |
flame atomic emission spectrometry |
0.0 |
0 |
102235 |
2682 |
SS/Hsd |
plasma sodium level |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
139.6 |
mmol/l |
1.9 |
4.65 |
flame atomic emission spectrometry |
0.0 |
0 |
102243 |
2682 |
SR/Hsd |
plasma sodium level |
controlled sodium content diet (0.4 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) then sham surgical control condition (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
140.8 |
mmol/l |
1.6 |
3.92 |
flame atomic emission spectrometry |
0.0 |
0 |
102249 |
2682 |
SS/Hsd |
plasma sodium level |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) then surgical denervation (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
140.4 |
mmol/l |
1.1 |
2.69 |
flame atomic emission spectrometry |
0.0 |
0 |
102256 |
2682 |
SR/Hsd |
plasma sodium level |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then Gnai2 antisense oligonucleotide (4.17 ug/d) (for 21 days) then surgical denervation (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
140.7 |
mmol/l |
0.9 |
2.2 |
flame atomic emission spectrometry |
0.0 |
0 |
102252 |
2682 |
SS/Hsd |
plasma sodium level |
controlled sodium content diet (8 %) (for 21 days) then intracerebroventricular cannula implantation then scrambled control oligodeoxynucleotide (4.17 ug/d) (for 21 days) then sham surgical control condition (for 21 days) |
Wainford RD, et al., Hypertension. 2015 Jan;65(1):178-86. doi: 10.1161/HYPERTENSIONAHA.114.04463. Epub 2014 Oct 13. |
blood sodium amount |
male |
91 days-119 days |
6 |
138.9 |
mmol/l |
1.2 |
2.94 |
flame atomic emission spectrometry |
0.0 |
0 |
102255 |
2682 |